 AUSTIN, Texas, March 10, 2021 PRNewswire -- Luminex Corporation NASDAQ: LMNX today announced that it has submitted an Emergency Use Authorization application to the U.S. Food and Drug Administration for the companys new multi-analyte respiratory panel combining Flu AB and respiratory syncytial virus RSV targets with the SARS-CoV-2 target. The ARIES Flu AB RSVSARS-CoV-2 Assay can be run on all Luminex ARIES Systems. 